Our Therapy
Photodynamic therapy (PDT) for KLAS-PDT
Thanks to KLAS Therapeutics, PDT therapy can be used for the first time in the fight against malignant melanoma. Our patented technology allows PDT to target the melanoma cells with pre-clinical studies showing 500% tumour size reduction compared to PDT alone and eradication of nearly 100% of melanoma cells.
Can be used as a synergistic approach with current immunotherapies meaning lower toxicity with increased tolerance.
Providing hope for the future for melanoma patients
Klas Therapeutics has developed KLAS-PDT, an advanced photodynamic therapy for malignant melanoma. This patented technology significantly reduces tumour size and minimizes systemic side effects and scarring. KLAS-PDT is not only effective but also more affordable than existing treatments, providing a promising new option for patients battling melanoma.
Klas-PDT, our proprietary photodynamic therapy, represents a significant advancement in the treatment of malignant melanoma. This technology leverages light-activated compounds to target and destroy cancer cells with precision, offering several benefits over traditional treatments.
Short video explaining the Klas Therapeutics lead compound
Meet the CEO and Co-Founder
Bridgeen completed her degree and PhD in Physical Organic Chemistry at Queens University Belfast in 2006. She spent a few years at Aberdeen’s Robert Gordon University before returning to Northern Ireland in 2009 as an academic at Ulster University’s School of Pharmacy. Bridgeen received her professorship in 2023, and having founded Klas Therapeutics in 2021, became the spin-out’s Chief Executive Officer in 2023.
Bridgeen has an internationally recognised research career, having received significant research income, published numerous research articles and supervised a large number of PhD students. She is passionate about chemistry and in particular the role of women in science as well as female founders. As the CEO of Klas, she is driving the technology forward with her commitment, enthusiasm and work ethic using the skills developed as a successful academic and translating these to achieve the global vision adopted by Klas Therapeutics of improving the lives of melanoma patients.
Key Advantages
Significant Tumor Reduction
Achieves up to a 500% reduction in tumour size in pre-clinical studies. Demonstrating a therapy that could potentially significantly improve treatment efficacy.
Minimal Side Effects
Focuses on the tumor site, reducing systemic toxicity and sparing healthy tissue.
Cost-Effective
Provides an affordable alternative to existing cancer treatments, making it accessible to a broader patient population.
Pre-Clinical Success
Demonstrated near-total eradication of melanoma cells in vitro, showcasing its potential for clinical success.
Investment Opportunities
KLAS Therapeutics is actively seeking investors who want to make a real difference in the lives of Melanoma sufferers and to become a part of a dynamic team that seeks to push the boundaries of current medical therapies.